The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer.
C. J. Allegra
Consultant or Advisory Role - Genentech (U)
G. A. Yothers
Consultant or Advisory Role - Roche/Genentech (U)
M. J. O'Connell
Consultant or Advisory Role - Roche; Sanofi
S. Sharif
No relevant relationships to disclose
N. J. Petrelli
Consultant or Advisory Role - Genentech
L. H. Colangelo
No relevant relationships to disclose
N. Wolmark
Consultant or Advisory Role - Roche/Genentech (U)